Results 31 to 40 of about 11,453 (268)
Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]
, 2017 BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence +7 more
core +1 more source
Safety and efficacy of low-dose and long-course tirofiban in large hemispheric infarction
Frontiers in Neurology, 2022 BackgroundThe clinical efficacy and safety of tirofiban in the treatment of large hemispheric infarction (LHI) remain controversial.MethodsThis study prospectively enrolled patients with acute LHI who were admitted to Putuo Hospital affiliated with ...
Yinqin Hu +6 more
doaj +1 more source
Are tirofiban and abciximab identical in efficacy? [PDF]
European Heart Journal, 2005 We read the paper by Mukherjee et al .1 on similar efficacy outcomes with tirofiban and ReoPro with a lot of interest and considerable reservations. The paper was hand-delivered to me by the representative of one of the drugs in the study with the proud claim that both drugs were equivalent.
openaire +3 more sources
Journal of Cardiovascular Development and Disease, 2022 Tirofiban has recently shown encouraging efficacy and safety among acute ischemic stroke (AIS) patients with mechanical thrombectomy (MT). However, the benefits of tirofiban varied among studies depending on the patient’s condition, which was often not ...
Lingxin Cai +6 more
doaj +1 more source
Hydration versus N-acetylcysteine for protection of renal function in patients with renal insufficiency undergoing percutaneous coronary intervention [PDF]
, 2003 A Clarion Call for Large-Scale Collaborative Studies of Pediatric Proton ...
Berrington de Gonzalez, Amy +14 more
core +1 more source
Tirofiban and emergency coronary surgery [PDF]
European Journal of Cardio-Thoracic Surgery, 2005 The final common pathway of platelet aggregation leading to coronary thrombosis involves cross-linking of platelet receptor glycoprotein IIb-IIIa by primarily fibrinogen. Glycoprotein IIb-IIIa antagonists are being increasingly used as adjunctive therapy during percutaneous coronary intevention, and have shown to reduce the risk of death and myocardial
openaire +3 more sources
Glycoprotein IIb/IIIa Inhibitors Use and Outcome after Percutaneous Coronary Intervention for Non-ST Elevation Myocardial Infarction [PDF]
, 2014 Aims. We investigate the effect of glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors on long-term outcomes following percutaneous coronary intervention (PCI) after non-ST elevation myocardial infarction (NSTEMI). Meta-analyses indicate that these agents are
Antoniou, S +9 more
core +4 more sources
Chronic Diseases and Translational Medicine, 2015 Objective: To evaluate the efficacy and short term prognosis of Tirofiban in different treatment duration in patients with acute ST segment elevation myocardial infarction (STEMI) and percutaneous coronary intervention (PCI) combined with intracoronary ...
Zhen-Guo Ji +6 more
doaj +1 more source
Long-Term Outcomes of Local Tirofiban Infusion for Intracranial Atherosclerosis-Related Occlusion
Brain Sciences, 2022 Local tirofiban infusion has been reported as a rescue strategy for intracranial atherosclerotic stenosis (ICAS)-related stroke. However, the long-term outcomes of local tirofiban infusion during endovascular reperfusion therapy (ERT) for ICAS-related ...
Woochan Choi +2 more
doaj +1 more source
Biochemistry Research International, 2020 Introduction. Limited comparative studies have reported the safety and efficacy of tirofiban in acute ischemic stroke (AIS) patients after mechanical thrombectomy (MT).
Lili Zhao +15 more
doaj +1 more source